Dr. Sagar
Parikh, MD Appointed to
NeonMind Specialty Clinics Advisory Board
Vancouver,
B.C. – July 28, 2021 -- InvestorsHub NewsWire -- NeonMind
Biosciences Inc. (CSE:
NEON) (OTC:
NMDBF) (FFE:
6UF) ("NeonMind''
or the "Company"),
an integrated drug development and wellness company focused on the
potential therapeutic uses of psilocybin for treating obesity and
weight management conditions, announced today the appointment of
Dr. Sagar Parikh, MD to its Specialty Clinics Advisory
Board. In this
role, Dr. Parikh will leverage his vast expertise in clinical
treatment and interventional psychiatry including effectively
treating patients with psychedelics such as ketamine, esketamine,
and neurostimulation for mood and anxiety
disorders
to guide NeonMind as it develops specialty clinic services for
communities in need.
Dr. Parikh has served as the
John F. Greden Professor of Depression and Clinical Neuroscience,
and Professor of Psychiatry, at the University of Michigan, Ann
Arbor since 2015, where he was also
designated Associate Director of the Michigan Comprehensive
Depression Center. He is an adjunct Professor of Psychiatry at the
University of Toronto, where he was on staff full-time from
1994-2015. He serves as the Medical Director at the National Network of
Depression Centers, completed two terms as Deputy
Psychiatrist-in-Chief at Toronto's major hospital grouping, the
University Health Network, and was head of the Bipolar Clinic and
Director of CME at the Centre for Addiction and Mental Health (CAMH) in
Toronto.
"Dr. Parikh brings unmatched
experience to guide the development and integration of the most
effective and cutting-edge protocols and treatment modalities for
our expected specialty clinic rollout. We are committed to
ensuring
that every patient receives tailored, personalized care and each
clinic is designed to meet needs of the local community where it
will be located. Dr. Parikh's expert leadership will ensure that we
offer best-in-class medical services and programs to
every patient,"
said Robert Tessarolo, President & CEO of NeonMind.
On his appointment, Dr.
Parikh said, "NeonMind is developing a network of clinics that is
truly unique in its specialization and breadth of treatment
offerings. As mental health care continues to evolve at a rapid
pace with new treatments and protocols, NeonMind will be well
positioned to have the programs, infrastructure, and education in
place to safely and effectively administer these
treatments."
Dr. Sagar Parikh is the
author/editor of three books and over 200
peer-reviewed articles and book chapters, and co-author of CANMAT
treatment guidelines for Depression and for Bipolar Disorder, the
world's most cited mood disorder guidelines. He holds research
grants from multiple funding agencies, covering studies in
clinical treatments in mood disorders, health services research,
genetics, epidemiology, and educational research. He has conducted
clinical trials looking at the combination of medication and
psychotherapy for bipolar disorder and for depression, as well as
pharmacotherapy trials in mood disorders.
About NeonMind Biosciences Inc.
NeonMind is engaged in
preclinical research to develop potential clinical treatments and
wellness products to address obesity and weight management
conditions
and to promote health and wellness. The Company operates three
divisions: (i) a pharmaceutical division engaged in drug
development of psychedelic compounds with two lead psilocybin-based
drug candidates targeting obesity; (ii) a medical services
division
focused on launching specialty mental health clinics that integrate
psychedelic therapeutics into traditional psychotherapy settings;
and (iii) a consumer products division that currently sells
mushroom-infused products to promote health and
wellness.
In its pharmaceutical
division, NeonMind has two distinct psilocybin drug development
programs targeting obesity. NeonMind's first drug candidate employs
psilocybin as an agonist at the serotonin 5- HT2A receptor, which
is involved in the hallucinogenic effect of psychedelics.
The Company's second drug candidate employs low-dose psilocybin as
an agonist at the 5-HT2C receptor, which controls
appetite.
NeonMind established a
medical services division with the goal of launching
NeonMind-branded specialty mental health clinics in
Canada that incorporate evidence-backed innovative treatments to
address a variety of mental health needs.
NeonMind's consumer division
currently sells NeonMind-branded coffee products in the United
States and Canada through NeonMind's direct to consumer
e-commerce platform.
For more information on
NeonMind, go to www.NeonMindBiosciences.com.
Rob
Tessarolo, President & Chief Executive Officer, NeonMind
Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101
Investor
Relations:
KCSA
Strategic Communications
Scott
Eckstein/Tim Regan
neonmind@kcsa.com
Tel: 212-896-1210
Media
Inquiries:
KCSA
Strategic Communications
Annie
Graf
neonmind@kcsa.com
Tel: 786-390-2644
The
Canadian Securities Exchange has not reviewed, approved nor
disapproved the contents of this news release.
Cautionary
Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or NeonMind's future performance. The use of any of the
words "could", "expect", "believe", "will", "projected",
"estimated"
and similar expressions and statements relating to matters that are
not historical facts are intended to identify forward-looking
information and are based on NeonMind's current belief or
assumptions as to the outcome and timing of such future events.
Actual
future results may differ materially. In particular, NeonMind's
drug development plans, its ability to retain key personnel, and
its expectation as to the development of its intellectual property
and other steps in its preclinical and clinical drug
development
constitute forward-looking information. Actual results and
developments may differ materially from those contemplated by
forward-looking information. Readers are cautioned not to place
undue reliance on forward-looking information. The statements
made in this press release are made as of the date hereof. NeonMind
disclaims any intention or obligation to publicly update or revise
any forward-looking information, whether as a result of new
information, future events or otherwise, except as may be
expressly
required by applicable securities laws.